Spark Therapeutics’ SPK-8011, an investigational gene therapy treatment for hemophilia A, was successful in reducing bleeding in a phase 1/2 trial, but also resulted in one of the participants getting hospitalized.
Summit Therapeutics said that its oral small molecule antibiotic ridinilazole was successful in preserving the gut microbiome of patients with C. difficile infection (CDI) during a phase 2 trial.
Arrowhead Pharmaceuticals has secured a $10m milestone payment from Amgen, following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study.
Clinical-stage drug development firm Karuna Pharmaceuticals has completed $42m Series A financing round to advance selective muscarinic receptor agonist program into phase 2 study.
Celtaxsys' cystic fibrosis (CF) drug acebilustat has showed clinically meaningful improvements in pulmonary exacerbations in the phase 2 Empire-CF trial.
Genkyotex said that US National Institutes of Health (NIH) has awarded an $8.9m grant to Professor Victor Thannickal at the University of Alabama at Birmingham (UAB) to fund a multi-year research program to assess the role of NOX enzymes in idiopathic pulmonary fibrosis (IPF).
Emergent BioSolutions has initiated a phase 1 clinical study to assess the safety and pharmacokinetics of its anti-Zika virus immune globulin ZIKV-IG, which is being developed as a therapeutic intervention against Zika virus disease.
RedHill Biopharma’s RHB-104 orally-administered antibiotic combination therapy has achieved its primary endpoint and key secondary endpoints in phase III Crohn’s disease study.
Destiny Pharma, a UK-based clinical stage biotechnology company, has reported positive data for its synthetic antimicrobial drug XF-73 from a phase 1 skin irritation study.
Takeda’s lung cancer drug Alunbrig (brigatinib) has significantly improved progression-free survival (PFS) in phase 3 ALTA-1L (ALK in lung cancer trial of AP26113 in 1st line) trial.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.